



Pathology | Radiology | Consultations (<u>A Brand of Dr Laksandan Labs Limited</u> (On CGHS Fonel)

14.11.2018

To The Secretary, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Scrip Code - 541299

Sub- Sub: Outcome of Board Meeting held on 14th November, 2018 and Submission of Standalone Unaudited Financial Results for the half year ended on 30th September, 2018.

Dear Sir/Madam,

We would like to inform you that the meeting of the Board of Directors of the Company was held today, 14th November, 2018 at registered office of the company at M-20, Basement, GK-1, South Delhi-110048 at 2.00 PM, and has transacted the following:

 Considered and approved Standalone Unaudited Financial Results (Standalone) for the Half Year ended on 30th September, 2018 along with the Limited Review Report thereon issued by Statutory Auditors for the half year ended on 30th September, 2018.

Copy of the Standalone Unaudited Financial Results along with the Independent Auditor's Limited review report are attached herewith.

The meeting of the Board of Directors commenced at 2.00 pm and concluded at 6.35 p.m.

Please take the same on your records.

Yours Faithfully Dr Lalchandani Labs Limited NEW DELHI 3 Mohit Lalchandani Whole Time Director DIN- 07873508

Encl: As Above

M-20, GK-1, Main Road, New Delhi - 110048

011-49057058/9 80-10-689-689

www.lalchandanigathlab.com

AASM & Co.

Chartered Accountants



INDEPENDENT AUDITOR'S REVIEW REPORT

Review Report to Board of Directors Dr Lalchandani Labs Limited

We have reviewed the accompanying Statement of standalone unaudited financial results of **Dr Lalchandani Labs Limited** ('the Company') for the half year ended on 30th September, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For AASM & Co. Chartered Accountants FRN-030481N

M&

New Delhi 030481N

ered Acc


Ashish Arora Partner

M.No- 516241 Place: New Delhi

Date : 14/11/2018

<u>Corporate Office</u> – H-7, Lower Ground Floor, Green Park Extension, New Delhi – 110016 <u>Contact</u> – +91-11-46566386 <u>Email</u> – info.aasm@gmail.com





Pathology | Radiology | Consultations (<u>A Brand of Dr Lakhandani Labs Limited</u>) (On CGHS Ponel)

| Sr. No. | Particulars | As at 30.09.2018 | As at 31.03.2018 Audited | |
|------------|---|---------------------|--------------------------------|--|
| NO. | | Un-audited | | |
| 1 | Shareholders' Funds | | | |
| | (a) Share Capital | 433.31 | 293.31 | |
| | (b) Reserves and Surplus | 339.50 | 39.98 | |
| | (c) Money received against share warrants | | - | |
| | Sub-total-Shareholders' Funds | 772.81 | 333.29 | |
| 2 | Share application money pending allotment | | | |
| 3 | Non Current Liabilities | | | |
| | (a) Long Term Borrowings | 56.02 | 182.37 | |
| | (b) Deferred Tax Liability | 2.39 | 2.39 | |
| | (c) Other Long Term Liabilities | - | - | |
| | (d) Long Term Provisions | - | - | |
| | Sub-total-Non Current Liabilities | 58.41 | 184.76 | |
| 4 | Current Liabilities | | | |
| | (a) Short Term Borrowings | 5.05 | 5.06 | |
| | (b) Trade Payables | 84.22 | 68.17 | |
| | (c) Other Current Liabilities | 12.48 | 21.87 | |
| | (d) Short Term Provisions | 13.88 | 7.03 | |
| | Sub-total-Current Liabilities | 115.63 | 102.13 | |
| | TOTAL EQUITY AND LIABILITIES | 946.85 | 620.18 | |
| П | ASSETS | | | |
| 1 | Non-Current Assets | | | |
| | (a) Fixed Assets | | | |
| | (i) Tangible assets | 297.81 | 205.36 | |
| | (ii) Intangible assets | 17.42 | 0.45 | |
| | (b) Non Current Investments | 24.10 | 24.10 | |
| | (c) Long Term Loans & Advances | - | - | |
| | (d) Other Non Current Assets | 57.17 | 8.25 | |
| | Sub-total-Non Current Assets | 396.50 | 238.16 | |

STANDALONE STATEMENT OF ASSETS AND LIABILITIES




Dr Lalchandani Labs Limited

🎱 M-20, GK-1, Main Road, New Delhi - 110048

011-49057058/9 80-10-689-689





Pathology | Radiology | Consultations (<u>A Brand of Dr Lakhandani Labs Limited</u>) (On CGHS Panel)

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

| | Amount in Rs. (Lacs) | | | | |
|------------|---------------------------------|------------------|--------------------------------|--|--|
| Sr. No. | Particulars | As at 30.09.2018 | As at 31.03.2018 Audited | | |
| NO. | | Un-audited | | | |
| 2 | Current Assets | | | | |
| 2 | (a) Current Investments | | - | | |
| | (b) Inventories | 28.30 | 27.12 | | |
| 1 | (c) Trade Receivables | 182.98 | 112.06 | | |
| | (d) Cash & cash equivalents | 130.77 | 90.86 | | |
| | (e) Short Term Loans & Advances | 105.77 | 107.89 | | |
| | (f) Other Current Assets | 102.53 | 44.09 | | |
| | Sub-total-Current Assets | 550.35 | 382.02 | | |
| | TOTAL ASSETS | 946.85 | 620.18 | | |

For Dr Lalchandani Labs Limited

NDANI NEW DELHI IMI (Mohit Lalchandani) Whole Time Director (DIN: 07873508) *

New Delhi 14-Nov-18

M-20, GK-1, Main Road, New Delhi - 110048

0

011-49057058/9 80-10-689-689





Pathology | Radiology | Consultations (A Brand of Dr Lalchandan: Labs Limited) (On CGHS Panel)

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2018

| | Amount Rs. (in Lacs) | | | | | | |
|------------|--|-----------------|------------|-----------------------|------------------------|--|--|
| Sr. No. | Particulars | Half Year Ended | | For the Year Ended | Previous Year Ended | | |
| | | 30.09.2018 | 30.09.2017 | 31.03.2018 | 31.03.2017 Audited | | |
| | | Un-audited | Audited | Audited | | | |
| 1 | Revenue from Operations | 261.70 | 264.86 | 494.45 | 452.02 | | |
| 11 | Other Income | - | 0.92 | 2.70 | 8.93 | | |
| | Total Revenue(I+II) | 261.70 | 265.78 | 497.15 | 460.95 | | |
| IV | Expenses | | | | | | |
| | (a) Cost of materials consumed | 62.74 | 60.13 | 110.17 | 206.14 | | |
| | (b) Purchases of stock in trade | 40.15 | 58.23 | 112.44 | 207.38 | | |
| | (c) Changes in inventories of finished goods, work in progress and stock in trade | - 1.18 | 1.91 | - 2.27 | - 1.24 | | |
| - | (d) Employee benefits expense | 41.79 | 28.87 | 70.78 | 35.97 | | |
| | (e) Finance Cost | 8.87 | 13.74 | 26.19 | 35.83 | | |
| | (f) Depreciation and amortisation expense | 15.22 | - | 13.08 | 16.93 | | |
| | (g) Other Expenses | 106.72 | 61.22 | 159.57 | 95.35 | | |
| | Total Expenses | 235.34 | 163.96 | 379.78 | 390.22 | | |
| V | Profit before exceptional and extraordinary items and tax (III - IV) | 26.36 | 101.82 | 117.36 | 70.73 | | |
| VI | Exceptional Items | | _ | - | - | | |
| VII | Profit extraordinary items and tax (V - VI) | 26.36 | 101.82 | 117.36 | 70.73 | | |
| VIII | Extraordinary Items | | | - | - | | |
| IX | Profit before tax (VIII - VIIII) | 26.36 | 101.82 | 117.36 | 70.73 | | |
| Х | Tax Expenses : | | | | | | |
| | (1) Current Tax | 6.85 | 25.31 | 32.14 | 21.86 | | |
| | (2) Deferred Tax | - | - | 2.39 | - | | |
| XI | Profit / (Loss) from Period from continuing oprtstions (VII -VIII) | 19.51 | 76.51 | 82.84 | 48.87 | | |
| XII | Profit (Loss) from discontinuing Operations | - | - | - | - | | |
| XIII | Tax Expense of Discontinuing operations | - | - | - | - | | |

📍 M-20, GK-1, Main Road, New Delhi - 110048

NDANIL





Pathology | Radiology | Consultations (A Brand of Dr Lalchandani Labs Limited) (On CGHS Panel)

| | | Amount Rs. (in Lacs) | | | |
|-----|--|----------------------|------------|-----------------------|------------------------|
| Sr. | Particulars | Half Year Ended | | For the Year Ended | Previous Year Ended |
| No. | | 30.09.2018 | 30.09.2017 | 31.03.2018 | 31.03.2017 |
| | | Un-audited | Audited | Audited | Audited |
| XIV | Profit / (Loss) from Discontinuing oprtstions (After Tax XII- XIII) | - | - | - | - |
| XV | Profit (Loss) for the period (XI +XIV) | 19.51 | 76.51 | 82.84 | 48.87 |
| XVI | Earnings Per Share of Rs. 10 Each (Not Annualised) | | | | |
| | (a) Basic (Rs.) | 0.45 | 5.45 | 2.82 | 5.32 |
| | (b) Diluted (Rs.) | 0.45 | 5.45 | 2.82 | 5.32 |

Notes:

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 14th November, 2018.

2. There were no investor complaints received / pending as at 30th September, 2018

3. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.

For Dr Lalchandani Labs Limited NEW DELHI AL (Mohit Lalchandani) Whole Time Director (DIN:07873508) New Delhi 14-Nov-18

M-20, GK-1, Main Road, New Delhi - 110048

